Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Sep;70(9):2719-2722.
doi: 10.1111/jgs.17895. Epub 2022 May 25.

Newer glucose-lowering drugs and risk of dementia: A meta-analysis of cardiovascular outcome trials

Huilin Tang  1 , Shu Niu  1 , Joshua Brown  1   2 , Jingkai Wei  3 , Hui Shao  1   2 , Jiang Bian  4 , Jingchuan Guo  1   2
Affiliations
Meta-Analysis

Newer glucose-lowering drugs and risk of dementia: A meta-analysis of cardiovascular outcome trials

Huilin Tang et al. J Am Geriatr Soc. 2022 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

Figures

Figure 1.
Figure 1.
Meta-analysis of the effects of novel glucose-lowering drugs on the risk of all-cause dementia in participants with or without type 2 diabetes. OR, odds ratio; CI, confidence interval; DPP-4 inhibitors, dipeptidyl peptidase-4 inhibitors; GLP-1RAs, glucagon-like peptide-1 receptor agonists; SGLT2 inhibitors, sodium-glucose co-transporter-2 inhibitors.
Figure 2.
Figure 2.
Meta-analysis of the effects of novel glucose-lowering drugs on the risk of vascular dementia in participants with or without type 2 diabetes. OR, odds ratio; CI, confidence interval; DPP-4 inhibitors, dipeptidyl peptidase-4 inhibitors; GLP-1RAs, glucagon-like peptide-1 receptor agonists; SGLT2 inhibitors, sodium-glucose co-transporter-2 inhibitors.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bello-Chavolla OY, Antonio-Villa NE, Vargas-Vazquez A, Avila-Funes JA, Aguilar-Salinas CA. Pathophysiological Mechanisms Linking Type 2 Diabetes and Dementia: Review of Evidence from Clinical, Translational and Epidemiological Research. Curr Diabetes Rev. 2019;15(6): 456–470. - PubMed
    1. Zhou JB, Tang X, Han M, Yang J, Simo R. Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis. Metabolism. 2020;109154265. - PubMed
    1. Wium-Andersen IK, Osler M, Jorgensen MB, Rungby J, Wium-Andersen MK. Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study. Eur J Endocrinol. 2019;181(5): 499–507. - PubMed
    1. Tang H, Kimmel SE, Hernandez I, et al. Are novel glucose-lowering agents’ cardiorenal benefits generalizable to individuals of Black race? A meta-trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment. Diabetes Obes Metab. 2022;24(1): 154–159. - PubMed
    1. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007;26(1): 53–77. - PubMed

Publication types